Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 302

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 302
---
 to be issued, if converted, would be equal to the unpaid principal amount and accrued and unpaid
interest thereon divided by the closing price of our common stock on the date that is one day prior to such election.

We plan to continue to fund losses from operations
and future funding needs through our cash on hand and future potential equity and/or debt offerings. There are a number of uncertainties
associated with our ability to raise additional capital and we have no current arrangements with respect to any additional financing.
If we raise funds from the issuance of equity securities (which will be challenging in light of current market conditions combined with
our limited technologies), substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring
debt financing (also challenging in light of current market conditions combined with our limited technologies), the terms of the debt
may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate
our business. Since the closing date of the Reverse Merger, our limited cash position has required us to perform only limited development
activities and to delay and scale back our development programs and other activities to remain afloat. If we continue to have insufficient
funds, we may be required to cease our operations altogether.

In addition, the continuation of disruptions caused
by COVID-19 or other related variants, broad-based inflation, and various economic indicators that the United States economy may be entering
a recession in upcoming quarters may cause investors to slow down or delay their decision to deploy capital which will adversely impact
our ability to fund future operations. Consequently, there can be no assurance that any additional financing on commercially reasonable
terms, or at all, will be available when needed. If we are unable to raise additional capital and continue to have insufficient funds,
we may be required to cease our operations altogether. The above matters raise substantial doubt regarding our ability to continue as
a going concern.

Cash Flow Summary 

The following table provides a summary of our net
cash flow activity for the years ended December 31, 2024 and 2023:

    Year Ended
                                                                                December 31, 2024  
    Year Ended
                                                                                December 31, 2023 
  
    Net cash used in operating activities 
    $(241,159) 
    $(497,467)
  
    Net cash provided by investing activities 
     –  
     433,000 
  
    Net cash provided by financing activities 
     200,000